Parexel International Corp. (PRXL) Shares Down 4.5%
Parexel International Corp. (NASDAQ:PRXL) shares dropped 4.5% during trading on Wednesday . The stock traded as low as $67.36 and last traded at $67.91, with a volume of 663,326 shares trading hands. The stock had previously closed at $71.11.
PRXL has been the subject of several recent research reports. KeyCorp reissued a “hold” rating on shares of Parexel International Corp. in a research note on Sunday, May 22nd. Evercore ISI raised shares of Parexel International Corp. from a “hold” rating to a “buy” rating in a research note on Wednesday, June 1st. Jefferies Group reiterated a “hold” rating and issued a $70.00 price target on shares of Parexel International Corp. in a research note on Thursday, June 9th. Credit Suisse Group AG began coverage on shares of Parexel International Corp. in a research note on Monday, June 20th. They issued an “outperform” rating and a $75.00 price target for the company. They noted that the move was a valuation call. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $73.00 price target on shares of Parexel International Corp. in a research note on Monday, June 27th. Two analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $71.75.
The firm has a 50 day moving average price of $67.71 and a 200-day moving average price of $63.11. The company has a market cap of $3.61 billion and a P/E ratio of 23.63.
Parexel International Corp. (NASDAQ:PRXL) last released its earnings results on Wednesday, August 3rd. The company reported $0.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.93 by $0.01. During the same quarter last year, the company posted $0.79 earnings per share. The business had revenue of $538.60 million for the quarter, compared to analysts’ expectations of $532.41 million. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Equities analysts expect that Parexel International Corp. will post $3.92 EPS for the current year.
In other news, insider Gadi Saarony sold 2,500 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $70.05, for a total transaction of $175,125.00. Following the completion of the transaction, the insider now directly owns 9,417 shares in the company, valued at approximately $659,660.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director A Dana Callow, Jr. sold 3,000 shares of the stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $60.04, for a total value of $180,120.00. Following the transaction, the director now owns 34,072 shares of the company’s stock, valued at $2,045,682.88. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Parexel International Corp. stock. I.G. Investment Management LTD. raised its stake in shares of Parexel International Corp. (NASDAQ:PRXL) by 1.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,029 shares of the company’s stock after buying an additional 545 shares during the period. I.G. Investment Management LTD. owned approximately 0.06% of Parexel International Corp. worth $2,318,000 as of its most recent filing with the SEC.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.